• The aim is to evaluate a management program for direct oral anticoagulants (DOACs) in non-valvular atrial fibrillation (NVAF) patients according to their profiles, appropriateness of dosing, patterns of crossover, effectiveness and safety. (revclinesp.es)
  • The study of ABCB1 and CYP3A4/3A5 gene polymorphism genes is promising in terms of their influence on prothrombin time variability, the residual equilibrium concentration of direct oral anticoagulants (DOACs) in patients with atrial fibrillation and the development of new personalized approaches to anticoagulation therapy in these patients. (lww.com)
  • In my practice, I've used all the NOAC (novel anticoagulant) therapies available for stroke prevention in my nonvalvular atrial fibrillation patients. (ajmc.com)
  • I have used dabigatran in my nonvalvular atrial fibrillation patients. (ajmc.com)
  • Patients with nonvalvular atrial fibrillation can certainly be switched from warfarin therapy to a NOAC or a DOAC (direct oral anticoagulant). (ajmc.com)
  • The Clinical Decision Aid was created to assist in selecting anticoagulant therapies for patients with nonvalvular atrial fibrillation. (nih.gov)
  • Although direct oral anticoagulant (DOAC) therapy is a guideline-recommended strategy in patients with non-valvular atrial fibrillation (AF), it is frequently underutilized. (neurosciencecme.com)
  • Clinicians must be aware that patients in RE-LY, ROCKET AF, and ARISTOTLE were highly selected and therefore the trial results may not be applicable to all patients with atrial fibrillation (AF) in their practice.1-4 Baseline characteristics for the study populations are displayed in Table I. (acc.org)
  • Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. (bmj.com)
  • Q In patients with non-valvular atrial fibrillation requiring long term oral anticoagulant therapy, is fixed dose oral ximelagatran non-inferior to adjusted dose warfarin for preventing stroke and systemic embolism? (bmj.com)
  • Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). (druglib.com)
  • Further investigation is needed to determine the optimal management strategy in patients with atrial fibrillation requiring TI of anticoagulation. (druglib.com)
  • Scholars@Duke publication: Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. (duke.edu)
  • METHODS AND RESULTS: In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. (duke.edu)
  • Patients with atrial fibrillation scheduled for cardioversion or ablation therapy are at a heightened risk of stroke both pre and post-treatment, and require optimal protection from dangerous blood clots," said Professor John Camm, St George's University Hospital, London. (hospitalpharmacyeurope.com)
  • X-VeRT (EXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in subjects with non-valvular aTrial fibrillation scheduled for cardioversion) is a Phase IIIb prospective, randomised, open-label, parallel-group, active-controlled, multi-centre study of 1,500 patients with non-valvular AF cardioversion. (hospitalpharmacyeurope.com)
  • VENTURE-AF (A Randomised, Open-label, Active-controlled Multi-centre Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation) is a Phase IIIb randomised, open-label, active-controlled study in 200 patients with paroxysmal (occasional) or persistent non-valvular AF undergoing first catheter ablation. (hospitalpharmacyeurope.com)
  • The real-world status of proton pump inhibitor (PPI) use in patients with atrial fibrillation (AF) receiving antithrombotic treatment is largely unknown. (elsevierpure.com)
  • Factors associated with an increased risk of thromboembolic events in patients with atrial fibrillation (AF) include increasing age, rheumatic heart disease, poor left ventricular function, previous myocardial infarction, hypertension and a past history of a thromboembolic event. (aafp.org)
  • Background: We determined the long-term event incidence among elderly patients with nonvalvular atrial fibrillation in terms of history of stroke/transient ischemic attack (TIA) and oral anticoagulation. (elsevierpure.com)
  • Methods: Patients aged ≥75 years with documented nonvalvular atrial fibrillation enrolled in the prospective, multicenter, observational All Nippon Atrial Fibrillation in the Elderly Registry between October 2016 and January 2018 were divided into 2 groups according to history of stroke/TIA. (elsevierpure.com)
  • Conclusions: Patients aged ≥75 years with nonvalvular atrial fibrillation and previous stroke/TIA more commonly had subsequent ischemic and hemorrhagic events than those without previous stroke/TIA. (elsevierpure.com)
  • In the AFFIRM study (Atrial Fibrillation Follow-up Investigation of Rhythm Management), an insignificant trend toward increased mortality was noted in the rate control group, and importantly, no evidence suggested that the rhythm-control strategy protected patients from stroke. (medscape.com)
  • Background.Among patients with atrial fibrillation (AF), women are at higher risk of stroke than men. (smu.ac.za)
  • Using prospective cohort data from a large global population of patients with nonvalvular AF, we sought to identify any differences in the use of anticoagulants for stroke prevention in women and men. (smu.ac.za)
  • A total of 17 184 patients with newly diagnosed (.6 weeks) nonvalvular AF and .1 additional investigatordefined stroke risk factor(s) were recruited (March 2010 to June 2013). (smu.ac.za)
  • Objective To compare the efficacy, safety, and cost effectiveness of direct acting oral anticoagulants (DOACs) for patients with atrial fibrillation. (bmj.com)
  • Eligibility criteria for selecting studies Published randomised trials evaluating the use of a DOAC, vitamin K antagonist, or antiplatelet drug for prevention of stroke in patients with atrial fibrillation. (bmj.com)
  • Conclusions The network meta-analysis informs the choice of DOACs for prevention of stroke in patients with atrial fibrillation. (bmj.com)
  • Mes projets de recherche sont en lien avec la pharmacoépidémiologie, et particulièrement l'évaluation de la prescription/déprescription, de l'utilisation et des effets des médicaments en pratique clinique dans le but d'optimiser et d'individualiser le traitement chez les patients atteints de maladies chroniques, et en particulier chez les personnes âgées. (uclouvain.be)
  • Previous studies have shown a link between catheter ablation and a lower risk of dementia and premature death for patients with atrial fibrillation. (medicalxpress.com)
  • A new research paper titled "Cardiovascular events and death after catheter ablation in very old patients with nonvalvular atrial fibrillation" has been published inAging. (medicalxpress.com)
  • Results from a new clinical trial found overweight and obese patients with persistent and paroxysmal atrial fibrillation (AF) who lose weight prior to a catheter ablation procedure have improved clinical outcomes. (medicalxpress.com)
  • reported that miR-328 contributes to the adverse atrial electrical remodeling in dogs and patients with AF 7 . (nature.com)
  • Manesh R. Patel discusses his research group's retrospective analysis of data on digoxin use among patients with atrial fibrillation in the ROCKET AF trial. (jwatch.org)
  • Warfarin is commonly given to obese (and other) patients to prevent cerebrovascular events in atrial fibrillation , to treat or prevent deep venous thrombosis (DVT) and pulmonary embolism (PE), and to lower the risk of blood clots after cardiac-valve replacement, the authors write. (medscape.com)
  • On the basis of outcomes, there was no clear winner from a trial that directly compared two modern devices used in patients undergoing percutaneous left atrial appendage (LAA) closure. (medscape.com)
  • LAA closure devices were developed as an alternative to oral anticoagulation in patients with nonvalvular atrial fibrillation. (medscape.com)
  • The 2011 Focused Update on the Management of Patients with Atrial Fibrillation-by the American College of Cardiology Foundation (ACCF), the AHA, and the Heart Rhythm Society (HRS)-addressed the issue of strict versus lenient rate control in patients with AF. (ahrq.gov)
  • Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with NOAC or warfarin treatment in patients with non-valvular atrial fibrillation: a population based cohort study. (janusinfo.se)
  • Loikas D, Forslund T, Wettermark B, Schenck-Gustafsson K, Hjemdahl P, von Euler M. Increased thromboprophylactic treatment in patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences. (janusinfo.se)
  • Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction. (janusinfo.se)
  • The goals of medical therapy for patients with atrial fibrillation are to maintain sinus rhythm, avoid the risk of complications (eg, stroke), and minimize symptoms. (medscape.com)
  • Antiarrhythmic drug algorithm for the medical management of sinus rhythm in patients with atrial fibrillation. (medscape.com)
  • It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. (bvsalud.org)
  • atrial septal defect closure or has an ASD/PFO device. (who.int)
  • randomised controlled trial (Stroke Prevention using an Oral Thrombin Inhibitor in Atrial Fibrillation [SPORTIF] V). (bmj.com)
  • Komen J, Forslund T, Hjemdahl P, Wettermark B. Factors associated with antithrombotic treatment choices for stroke prevention in atrial fibrillation in the Stockholm region since the introduction of the NOACs. (janusinfo.se)
  • As AF contributes to pathologic atrial and ventricular remodeling, restoration of sinus rhythm can slow or, in some cases, reverse atrial dilatation and left ventricular dysfunction. (medscape.com)
  • Tachyarrhythmias and bradyarrhythmias generated by these agents can be of ventricular or atrial origin. (medscape.com)
  • If atrial fibrillation, develops this is a medical emergency as very rapid ventricular rates can develop. (msdmanuals.com)
  • BACKGROUND: During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. (druglib.com)
  • These findings strongly implicate rs6817105 minor allele in sinus node dysfunction and left atrial enlargement. (nature.com)
  • Atrial fibrillation (AF) is one of the most common arrhythmias. (nature.com)
  • Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States, with prevalence currently estimated at 6 million which is projected to increase to 12 million by 2030, in line with the aging population [1,2]. (efim.org)
  • Atrial fibrillation is the most common sustained cardiac rhythm disorder and affects 750,000 people in the UK. (hospitalpharmacyeurope.com)
  • By maintaining the atrial contribution to cardiac output, symptoms of heart failure and overall quality of life can improve. (medscape.com)
  • Nonvalvular atrial fibrillation increases the risk of thromboembolic strokes, ischemic strokes, and other thromboembolic events. (ajmc.com)
  • Atrial fibrillation (AF) has strong associations with other cardiovascular diseases, such as heart failure, coronary artery disease (CAD), valvular heart disease, diabetes mellitus, and hypertension. (medscape.com)
  • 1 See paragraphs 16-18 of document A69/10, based on data included in the Noncommunicable diseases progress monitor 2015, availab le at http://www.who.int/nmh/publications/ncd-progress-monitor-2015/en/ (accessed 10 October 2016). (who.int)
  • http://www.un.org/en/ga/search/view_doc.asp?symbol=A/RES/68/300 (accessed 10 October 2016). (who.int)
  • See the question and answer document available at http://www.who.int/nmh/events/2015/technical-note-qa-en.pdf?ua=1 (accessed 10 October 2016). (who.int)
  • 1 Availab le at http://www.who.int/nmh/events/2015/technical-note-en.pdf?ua=1 (accessed 10 October 2016). (who.int)
  • 3 See http://www.who.int/nmh/events/2015/bloomberg-data-for-health/en/ (accessed 10 October 2016). (who.int)
  • The goal of antiarrhythmic drug therapy is to reduce the duration and frequency of atrial fibrillation episodes, thus improving patient quality of life and symptoms. (medscape.com)
  • Atrial fibrillation (AF) is defined as a tachyarrhythmia of supraventricular origin leading to deterioration in mechanical function of the … atrium. (cyberounds.com)